Analyst's consensus: Teva Pharmaceuticals is undervalued

It seems Teva Pharmaceuticals's stock trades with a discount.The majority of the analysts thinks Teva Pharmaceuticals is currently underpriced. Currently the company is being followed by 13 analyst. The recommendations spread over: 3 times sell, 6 times hold and no buys. The average of the target prices for the stock is at 29,05 USD. This is more or less 54 percent more than the current price of 6555 USD. JP Morgan, KBC Securities and ABN AMRO recently provided recommendations for the stock.

Estimates for Teva Pharmaceuticals not very concentrated

equity research

Teva Pharmaceuticals's market capitalization is based on the number of outstanding shares around 5951,94 billion USD.

Historical stock prices Teva Pharmaceuticals past 10 years

stock tevapharmaceuticals

At 11.29 the stock trades 0,56 percent lower at 6555 USD. Nieuwsdienst: +31 084-0032-842

Copyright B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.